CA2365204C - Lipoxin compounds and their use - Google Patents

Lipoxin compounds and their use Download PDF

Info

Publication number
CA2365204C
CA2365204C CA002365204A CA2365204A CA2365204C CA 2365204 C CA2365204 C CA 2365204C CA 002365204 A CA002365204 A CA 002365204A CA 2365204 A CA2365204 A CA 2365204A CA 2365204 C CA2365204 C CA 2365204C
Authority
CA
Canada
Prior art keywords
carbon atoms
branched
straight chain
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002365204A
Other languages
English (en)
French (fr)
Other versions
CA2365204A1 (en
Inventor
Charles N. Serhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to CA002675416A priority Critical patent/CA2675416A1/en
Publication of CA2365204A1 publication Critical patent/CA2365204A1/en
Application granted granted Critical
Publication of CA2365204C publication Critical patent/CA2365204C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002365204A 1999-03-18 2000-03-14 Lipoxin compounds and their use Expired - Fee Related CA2365204C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002675416A CA2675416A1 (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12520999P 1999-03-18 1999-03-18
US60/125,209 1999-03-18
PCT/US2000/006583 WO2000055109A1 (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002675416A Division CA2675416A1 (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use

Publications (2)

Publication Number Publication Date
CA2365204A1 CA2365204A1 (en) 2000-09-21
CA2365204C true CA2365204C (en) 2009-10-27

Family

ID=22418667

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002365204A Expired - Fee Related CA2365204C (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use
CA002675416A Abandoned CA2675416A1 (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002675416A Abandoned CA2675416A1 (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use

Country Status (12)

Country Link
US (8) US6433202B1 (enExample)
EP (1) EP1163204B1 (enExample)
JP (1) JP2002539181A (enExample)
AT (1) ATE303355T1 (enExample)
AU (2) AU776271B2 (enExample)
CA (2) CA2365204C (enExample)
DE (1) DE60022327T2 (enExample)
DK (1) DK1163204T3 (enExample)
ES (1) ES2246230T3 (enExample)
HK (1) HK1043357B (enExample)
PT (1) PT1163204E (enExample)
WO (1) WO2000055109A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
WO2000054761A2 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Regulation of phospholipase d activity
HK1043357B (en) * 1999-03-18 2005-12-09 The Brigham And Women's Hospital, Inc. LIPOXIN compound and its use
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
US6409541B1 (en) * 2000-11-02 2002-06-25 Autonetworks Technologies, Ltd. Waterproof structure in cable insertion section, method of manufacturing the same, and die for waterproof molding
WO2002065303A1 (en) * 2001-02-13 2002-08-22 Fujitsu Limited Network terminal having power saving mode
DE60229640D1 (de) * 2001-03-02 2008-12-11 Brigham & Womens Hospital Lipoxin analoge als neue inhibitoren der angiogenese
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP1441715B1 (en) * 2001-11-06 2013-02-27 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
ATE382597T1 (de) 2002-06-17 2008-01-15 Resolvyx Pharmaceuticals Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004014835A2 (en) * 2002-08-12 2004-02-19 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
AU2009311748B2 (en) 2008-11-04 2014-08-21 Index Pharmaceuticals Ab Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
JP7550143B2 (ja) 2018-10-09 2024-09-12 ユニバーシティ オブ ロチェスター 外陰膣障害の治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US309533A (en) * 1884-12-23 Saw-tooth-swaging device
US54761A (en) * 1866-05-15 Improved egg-beater
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
HK1043357B (en) * 1999-03-18 2005-12-09 The Brigham And Women's Hospital, Inc. LIPOXIN compound and its use
WO2000054761A2 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Regulation of phospholipase d activity
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
EP1441715B1 (en) 2001-11-06 2013-02-27 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases

Also Published As

Publication number Publication date
AU2008207590A1 (en) 2008-09-25
DK1163204T3 (da) 2005-12-19
US7615576B2 (en) 2009-11-10
US6433202B1 (en) 2002-08-13
US6720354B2 (en) 2004-04-13
US20080064747A1 (en) 2008-03-13
EP1163204B1 (en) 2005-08-31
US7579494B2 (en) 2009-08-25
AU776271B2 (en) 2004-09-02
US20070259958A1 (en) 2007-11-08
US20100048702A1 (en) 2010-02-25
US20030069435A1 (en) 2003-04-10
HK1043357A1 (en) 2002-09-13
EP1163204A1 (en) 2001-12-19
WO2000055109A9 (en) 2001-12-27
DE60022327T2 (de) 2006-06-29
AU2008207590B2 (en) 2010-12-16
PT1163204E (pt) 2005-11-30
US7227031B2 (en) 2007-06-05
AU3743100A (en) 2000-10-04
US8022105B2 (en) 2011-09-20
ATE303355T1 (de) 2005-09-15
US20050192350A1 (en) 2005-09-01
CA2675416A1 (en) 2000-09-21
US6960674B2 (en) 2005-11-01
JP2002539181A (ja) 2002-11-19
WO2000055109A1 (en) 2000-09-21
DE60022327D1 (de) 2005-10-06
US6659282B2 (en) 2003-12-09
US20030191332A1 (en) 2003-10-09
CA2365204A1 (en) 2000-09-21
HK1043357B (en) 2005-12-09
US20030055275A1 (en) 2003-03-20
ES2246230T3 (es) 2006-02-16

Similar Documents

Publication Publication Date Title
AU2008207590B2 (en) Lipoxin compounds and their use
US6620919B2 (en) Lipoxin compounds and their use in treating cell proliferative disorders
US7825271B2 (en) Lipoxin compounds and their use in treating cell proliferative disorders
EP0703897A1 (en) Lipoxin compounds
AU2004235617B2 (en) Lipoxin compounds and their use
EP1586550A1 (en) Lipoxin compounds and their use
US20120010286A1 (en) Prevention of neutrophil recruitment
HK1075246A (en) Lipoxin compounds and their use
AU7177500A (en) Lipoxin compounds and their use in treating cell proliferative disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150316